Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation
Authors:
Open Access
- 22 August 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70580
Abstract
INTRODUCTION: Genome‐wide association studies have identified MS4A4A, a microglia‐enriched gene, as a modulator of Alzheimer's disease (AD) risk. Common variants in MS4A4A affect AD susceptibility, gene expression, triggering receptor expressed on myeloid cells 2 (TREM2) signaling, and microglial transcriptional states, but the gene's functional role remains unclear.METHODS: Using a novel model, we investigated the impact of Ms4a4a loss in the 5xFAD mouse model of amyloid beta (Aβ) accumulation.RESULTS: Ms4a4a deficiency reduced steady‐state Aβ levels and shortened its half‐life in brain interstitial fluid. Aged 5xFAD mice lacking Ms4a4a exhibited more compact plaques and lower overall plaque burden. Microglia deficient in Ms4a4a showed a pro‐inflammatory profile and elevated matrix metalloproteinase 9 (MMP‐9) production, which may facilitate Aβ degradation. Notably, human carriers of the AD‐resilient variant rs1582763 near MS4A4A also displayed increased cerebrospinal fluid MMP‐9 levels.DISCUSSION: Together, we show that Ms4a4a loss enhances Aβ clearance and reduces pathology, suggesting a protective mechanism that may inform microglia‐targeted AD therapies.Highlights: We examined the impact of Ms4a4a loss on amyloid beta (Aβ) pathology using a mouse model of Aβ accumulation (5xFAD). Ms4a4a loss reduces overall plaque burden and increases plaque compaction. Microglia lacking Ms4a4a are more pro‐inflammatory and produce more matrix metalloproteinase 9 (MMP‐9). Alzheimer's disease (AD) resilience variant carriers, MS4A4A rs1582763, exhibit significantly elevated levels of cerebrospinal fluid MMP‐9. Our findings suggest that reduction of MS4A4A may be a therapeutic approach for AD.Keywords
Funding Information
- National Institutes of Health (AG062734, AG058501)
- Chan Zuckerberg Initiative
- Edward N. and Della L. Thome Memorial Foundation
- National Institute on Aging (P30AG066444)
This publication has 76 references indexed in Scilit:
- Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and β subunit of the high-affinity IgE receptorGene, 2001
- Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading EnzymeJournal of Neuroscience, 2000
- Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological depositionNature Medicine, 2000
- Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by DegradationJournal of Biological Chemistry, 1998
- Degradation of Amyloid β-Protein by a Metalloprotease Secreted by Microglia and Other Neural and Non-neural CellsJournal of Biological Chemistry, 1997
- A Possible Role for Cathepsins D, E, and B in the Processing of β‐amyloid Precursor Protein in Alzheimer's DiseaseEuropean Journal of Biochemistry, 1997
- Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40)The Journal of Neuroscience, 1996
- Neutral endopeptidase can hydrolyze β-amyloid(1–40) but shows no effect on β-amyloid precursor protein metabolismPeptides, 1995
- Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce ?-amyloid fibrilsActa Neuropathologica, 1992
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992